Bone aluminum accumulation in hemodialysis patients: a longitudinal perspective.
Serial bone biopsies obtained from 19 chronic hemodialysis patients asymptomatic for bone disease were examined retrospectively. We found only modest amounts of stainable bone aluminum after the first few years of hemodialysis therapy. Over the ensuing 5 to 15 years, there was a progressive increase in stainable bone aluminum (% of total bone surface): 0 to 4.9 years, 19.9 +/- 3.8% (mean +/- SEM); 5.0 to 9.9 years, 28.4 +/- 5.3%; and greater than or equal to 10.0 years, 58.0 +/- 7.7%. At final biopsy, the extent of bone surface aluminum was significantly correlated with duration of hemodialysis therapy (r = 0.54) and with bone formation rate (BFR) (r = -0.54). Patients who developed aluminum-associated bone disease did not differ from other patients in duration of hemodialysis, intake of 1-hydroxylated vitamin D3 compounds, or the findings on early bone biopsy. High-turnover renal osteodystrophy remains the dominant bone lesion throughout the course of hemodialysis in patients with intact parathyroid glands. In individual patients, bone histology frequently changes over time and in some patients, aluminum-associated bone disease may improve spontaneously. Bone biopsy in an asymptomatic patient who has received hemodialysis therapy for less than 5 years does not appear to be useful in predicting the subsequent appearance of aluminum-associated bone disease.
Department of Medicine, Seattle Veterans Administration Medical Center.
J B
JB
Kopp
D L
DL
Andress
N A
NA
Maloney
D J
DJ
Sherrard
D000328:Adult; D000535:Aluminum / Q000008:administration & dosage / Q000032:analysis* / Q000378:metabolism; D001706:Biopsy; D001842:Bone and Bones / Q000032:analysis* / Q000378:metabolism / Q000473:pathology; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008875:Middle Aged; D006435:Renal Dialysis; D012189:Retrospective Studies; D013997:Time Factors
D000535:Aluminum